^
Association details:
| Biomarker: | FOLH1 expression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Pluvicto (lutetium Lu 177 vipivotide tetraxetan) (PSMA inhibitor, Beta radiation emitter) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
577O - PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
Published date:
09/13/2021
Excerpt:
mCRPC patients (pts) with high PSMA expression without discordant FDG avid disease on paired PSMA and FDG PET/CT scans received up to 6 cycles of Lu-PSMA-617 (6-8 GBq) every 6 weeks in conjunction with 200mg of pembrolizumab every 3 weeks for up to 2 years....PSA50-RR was 73% (27/37 [95% CI: 56-86]) and 7/9 (78%) pts with RECIST measurable disease had a partial response....The combination of Lu-PSMA-617 and pembrolizumab had promising activity.
Trial ID:
